Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Read more at MarketWatch
Topics
-
FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decades
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.CNBC - 1h -
FDA approves new type of non-opioid pain medication
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval is an ...The Hill - 10h -
FDA Approves Journavx Drug to Treat Pain Without Addiction Risk
The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive.The New York Times - 12h -
FDA approves new type of nonopioid painkiller for acute pain
The Food and Drug Administration approved a new type of nonopioid painkiller, Journaxv, or suzetrigine, drugmaker Vertex Pharmaceuticals said.NBC News - 13h -
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.CNBC - 2d -
Insomniac Games Teases Potential Return To The Movies Under Its New Leadership
Big changes are taking place at Marvel's Spider-Man developer Insomniac Games, and with new leaders stepping in to take over the studio, the team is once again interested in bringing some of its ...GameSpot - Jan. 22 -
Nose spray to treat depression? FDA approves first-of-its-kind medicine
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.The Hill - Jan. 22 -
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.CNBC - Jan. 21 -
Trump launches surprise meme coin just before inauguration, and its price soars
President-elect Donald Trump launched his own meme coin early Saturday morning, creating excitement in the cryptocurrency world as the price and market capitalization of the coin immediately soared.MarketWatch - Jan. 20
More from MarketWatch
-
Tech giants to turn into ‘Lagnificent 7’ as U.S. exceptionalism peaks, say Bank of America strategists
The ”Magnificent Seven” grouping of tech stocks that have powered markets is set to start lagging the market, a team of strategists says.MarketWatch - 11m -
Chevron logs its first refining loss in four years, sending stock lower
Chevron touted “record production” as well as stock buybacks and announced an increase in its quarterly dividend.MarketWatch - 32m -
‘I have a secret that’s slowly taking all the joy from my life’: I’m happily married for 25 years, but I made a big financial mistake. How do I fix this?
“Over the past couple years, I have fought to get therapy and medications to bring me back to myself.”MarketWatch - 43m -
Bond yields rise as traders eye tariff developments
Bond yields rose on Friday with investors paying attention to tariff news as key inflation data was set for release.MarketWatch - 43m -
Why there’s now ‘incredible demand for physical gold’ in New York markets
A rush on physical gold, thanks to President Donald Trump’s tariff threats, has fueled a rise in prices of the precious metal to fresh record highs.MarketWatch - 45m
More in Business
-
Swiss pharma giant Novartis posts better-than-expected fourth-quarter sales
Swiss pharmaceutical giant Novartis on Friday reported fourth-quarter results after repeatedly raising its full-year guidance.CNBC - 10m -
Tech giants to turn into ‘Lagnificent 7’ as U.S. exceptionalism peaks, say Bank of America strategists
The ”Magnificent Seven” grouping of tech stocks that have powered markets is set to start lagging the market, a team of strategists says.MarketWatch - 11m -
Why There’s Nowhere to Hide From Trump’s Tariffs
President Trump’s long-promised trade war could start as soon as Saturday, leaving companies scrambling for a workaround for their global supply chains.The New York Times - 30m -
Chevron logs its first refining loss in four years, sending stock lower
Chevron touted “record production” as well as stock buybacks and announced an increase in its quarterly dividend.MarketWatch - 32m -
Ex-Goldman analyst ordered to pay £587,000 for insider dealing
London court gives Mohammed Zina three months to pay the amount that is available from current assetsFinancial Times - 38m